WHO Issues Warning Over Critical Shortage of Weight-Loss Injections
Under a tenth of patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it publishes its first guidance on the therapies.
Given over a billion individuals worldwide now classified as obese, it is urging increased and just access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"Our new guidelines affirms that obesity is a chronic disease that can be treated with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major obstacles to widespread availability to the injections that can assist patients in reducing substantial body mass, notes the agency.
Skinny Jab Shortage
Even in the current most optimistic case, the production of such drugs could only cover approximately 100 million people – less than 10% of those who need them, according to the WHO.
The advice urges countries and companies to expand availability, by measures like voluntary licensing.
Exclusive production rights on a key compound – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Jabs Function
The injections imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people consume fewer calories.
People commonly start to lose weight after several weeks of starting on the regular doses.
Research points to people may regain a significant portion a year later of stopping the medication, when their usual food cravings come back.
Being above a healthy weight increases your risk for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity affects individuals in every country and was associated with 3.7 million deaths worldwide in 2024, according to the health agency.